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Role of coagulation factor Xa and protease-activated receptor
2 in human mesangial cell proliferation.
Background. Fibrin deposition and mesangial cell prolifer-
ation are frequently observed in the active type of mesangio-
proliferative glomerulonephritis. Coagulation factors, such as
factor V and factor Xa are colocalized with fibrin in the mesan-
gial areas in active type of IgA nephropathy with mesangial cell
proliferation. In this study, therefore, we studied the role of fac-
tor Xa and its receptor, protease-activated receptor 2 (PAR2)
in mesangial cell proliferation and fibrin deposition, and exam-
ined ant-proliferative effects of a specific factor Xa inhibitor,
DX-9065a, in cultured human mesangial cells.
Methods. To examine the effect of DX-9065a on the factor
Xa–induced proliferation of cultured human mesangial cells, we
measured thymidine incorporation and cell numbers. We also
examined the effect of DX-9065a on extracellular regulated ki-
nase (ERK) activation and fibrin production induced by factor
Xa in human mesangial cells.
Results. Factor Xa increased [3H]-thymidine incorporation
and cell numbers in a dose-dependent manner in mesangial
cells, which was inhibited by DX-9065a. DX-9065a also sup-
pressed factor Xa–triggered fibrin deposition on mesangial cell
surface. Factor Xa induced the activation of ERK in mesan-
gial cells and this activation was also completely inhibited by
DX-9065a, but not inhibited by PAR1 antagonist. Factor Xa–
induced cell proliferation and ERK activation were inhibited
by PD98059.
Conclusion. There results suggest that factor Xa can induce
mesangial cell proliferation through the activation of ERK via
PAR2 in mesangial cells and that PAR2 may play a crucial role in
the cell proliferation induced by factor Xa. Our results implicate
that DX-9065a may be a promising agent to regulate prolifer-
ation of mesangial cellss and inhibit the coagulation process in
mesangium.
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Locally accelerated coagulation accompanying fibrin
deposition is implicated in various active mesangioprolif-
erative glomerulonephritis, such as IgA nephropathy and
Henoch-Scho¨nlein purpura nephritis [1–3]. These studies
indicate that intraglomerular coagulation is involved in
the development of glomerular injury.
We previously found an intact form of cross-linked
fibrin in the mesangial areas in active types of mesan-
gioproilferative glomerulonephritis [3]. We also reported
that mesangial factor V expression accompanied by the
intact form of cross-linked fibrin deposition is often de-
tected in the active type of IgA nephropathy and that the
coagulation activity is increased in mesangial cells due
to increased expression of endogenous factor V activity
along with exogenous factor Xa [4], which is a serine pro-
tease involved in coagulation cascades and is known to
stimulate the proliferation of mesangial cells in vitro [5].
These results indicate that factor Xa might contribute to
the process by inducing mesangial cell proliferation along
with its coagulation activity.
Thrombin and several upstream serine proteases of the
extrinsic coagulation cascade activate a novel family of
cell-surface receptors, the protease-activated receptors
(PARs) [6, 7], and thereby exert various cellular effects
that play critical roles in subsequent inflammatory and
tissue repair processes as part of the normal response to
tissue injury [8–10]. Since the discovery of the thrombin
receptor as PAR1 by Vu et al in 1991 [11], four PARs
(PAR1, 2, 3, and 4) have been identified with distinct
N-terminal cleavage sites, tethered ligand pharmacology,
and protease agonists [12–14]. Peptide agonists to the
tethered ligand sequence of PAR1, 2, and 4 can acti-
vate these receptors independently of proteolysis and
have been extensively used to invoke the role of these
receptors in mediating the responses of protease ago-
nists. Factor Xa can activate PAR1 or PAR2 depending
on the cell type examined [15]. Recently, it has been re-
ported that factor Xa can activate endothelial cells via a
PAR2-dependent mechanism [16, 17]. However, the role
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of PARs in factor Xa–mediated mesangial proliferation
is not known.
DX-9065a is a selective inhibitor of factor Xa [18] and
has been reported to be an orally active anticoagulant
[19]. Concerning its specificity, kinetic study revealed that
DX-9065a competitively inhibited human factor Xa (Ki
value 0.041 lmol/L), and was about ten times more potent
than trypsin for the inhibition of factor Xa. Further, DX-
9065a showed almost no inhibition on the other enzymes
examined as follows: thrombin >2000, trypsin 0.62, chy-
motrypsin >2000, plasmin 23, tissue plaminogen activa-
tor (t-PA) 21, plasma kallikrein 2.3, and tissue kallikrein
1000 (Ki value, lmol/L) [19]. According to these results,
DX-9065a is considered to be a selective inhibitor for fac-
tor Xa. Previous studies showed that DX-9065a inhibits
mitogenic effects of factor Xa in human vascular smooth
muscle cells (VSMCs) [20] and human vascular endothe-
lial cells [21], and reduces the anticoagulant activity in
various animal models of thrombosis in rats, mouse, and
rabbits [22–26]. These date suggest that DX-9065a could
be a promising therapeutic agent for various inflamma-
tory and thrombotic diseases, including glomerulonephri-
tis in humans.
In the present study, therefore, we examined whether
factor Xa can induce proliferation of cultured human
mesangial cells and whether factor Xa can signal through
PAR2 and extracellular regulated kinase (ERK) in vitro.
The present study was also designed to show the effect
of DX-9065a in PAR2-mediated mesangial cell prolifer-
ation.
METHODS
Materials
Human factor Xa and human prothrombin were from
American Diagnostica Inc. (Greenwich, CT, USA). DX-
9065a was supplied by Daiichi Pharmaceuticals Co. Ltd.
(Tokyo, Japan). FR171113 (PAR1 antagonist) was a gen-
erous gift from Fujisawa Pharmaceutical Co. Ltd. (Os-
aka, Japan) [27, 28]. Human thrombin and recombinant
hirudin were from Sigma Chemical Co. (St. Louis, MO,
USA). Human PAR1 agonist peptide (SFLLRN) and
PAR2 agonist peptide (SLIGKV) were from Bachem
(Bubendorf, Switzerland). PD98059 [mitogen-activated
protein kinase (MAPK)/ERK inhibitor] was from Cal-
biochem (San Diego, CA, USA). Mouse anti-PAR2 and
normal rabbit IgG were from Zymed Laboratories Inc.
(South San Francisco, CA, USA). Human fibrinogen
was purified from plasma using nitroblue tetrazolium
(Nacalai Tesque, Kyoto, Japan) according to the method
by Vila et al [29]. The purity was certificated by the
dot immunobinding assay and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) yield-
ing two bands of 340,000 and 320,000, which correspond
to two types of fibrinogen heterogeneity [30]. Recombi-
nant human tumor necrosis factor-a (TNF-a) was pur-
chased from Genzyme (Kent, UK). Factor XIII was from
Protogen AG (La¨ufelfingen, Switzerland). Cultured hu-
man mesangial cells (Cryo NHMC, passage 3) were pur-
chased from BioWhittaker (Walkersville, MD, USA).
The strain was tested positive for fibronectin but nega-
tive for von Willebrand factor, and cytokeratins 18 and
19. Phenotypically stable mesangial cells, sixth to ninth
passages, were cultured on plastic dishes (Nalge Nunc In-
ternational, Roskilde, Denmark) and maintained in Way-
mouth’s MB 752/1 medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 1 mmol/L glutamine, penicillin
at 100 U/mL, streptomycin at 100 lg/mL (Invitrogen),
and 20% fetal calf serum (FCS) (Cansera International
Inc., Rexdale, Canada).
Cell proliferation assay
After human mesangial cells were seeded into 24-
well dishes (4 × 104 cells/well), grown to subconflu-
ence in the media containing 20% FCS for 48 hours and
were made quiescent by treating with the media contain-
ing 0.5% FCS for another 48 hours (serum starvation).
The medium was then replaced with fresh serum-free
media containing various concentrations of factor Xa.
Cells were treated with inhibitors for 60 minutes before
stimulation. During the last 6 hours, 2 lCi/mL of [3H]-
thymidine (Perkin Elmer, Boston, MA, USA) was added
to the media. To measure the amount of radioactivity in-
corporated into the cell nuclei, the cultures were washed
with phosphate-buffered saline (PBS) followed by 5%
trichloroacetic acid in PBS. The precipitates were then
lysed with 0.25 mol/L NaOH in 0.1% SDS. Radioactivity
was measured in a liquid scintillation counter (Beckman,
Palo Alto, CA, USA).
Premix WST-1 cell proliferation assay (Takara
Biomedicals, Otsu, Japan) was also performed to assess
cell proliferation. Quiescent cells grown in 96-well plates
(1 × 104 cells/well) were incubated for 48 hours in 100 lL
of the media containing 0.5% FCS and factor Xa. Four
hours after 10 lL of premix WST-1 solution was added
to the cultures at 37◦C, optical density at 450 nm was
measured. The data were normalized by dividing incor-
poration counts by the cell number and showed as fold
increases over control.
Evaluation of cell viability
Cell viability was evaluated by the amount of lac-
tate dehydrogenase (LDH) released from the cells. Hu-
man mesangial cells grown in 24-well plates (5.0 × 104
cells/well) were incubated for 48 hours in medium con-
taining 1 or 10 lmol/L DX-9065a. The medium was then
collected and the cells were lysed with 1% Triton X-
100 in PBS. LDH activity in the medium or cell lysate
was measured with an LDH assay reagent (Wako Pure
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Chemical Industries, Osaka, Japan). The percentage of
released LDH was calculated from the ratio of LDH ac-
tivity in the medium to the sum of the LDH activity in
the medium and that in the cell lysate.
Activation of ERK
Subconfluent human mesangial cells were serum
starved for 48 hours. After stimulation with 50 nmol/L
factor Xa in the presence or absence DX-9065a, PD98059,
or FR171113, cells were washed with ice-cold PBS twice
and lysed by the lysis buffer accompanied with p44/42
MAPK (Thr202/Tyr204) Kinase Assay Kit (Cell Signal-
ing, Beverly, MA, USA) for 20 minutes on ice. Cell lysates
were collected, vortexed, and centrifuged at 12,000 rpm
for 15 minutes at 4◦C. Protein concentration of the super-
natant was measured using a BCA protein assay reagent
(Pierce, Rockford, IL, USA) and then immunoprecip-
itation was performed by Immobilized Phospho-p44/42
MAPK (Thr202/Tyr204) Monoclonal Antibody accord-
ing to the manufacturer’s instructions. The immunopre-
cipitates were then subjected to 10% SDS-PAGE and
transferred to nitrocellulose filters (Schleicher & Schuell
Inc., Keene, NH, USA). The blots were subsequently in-
cubated with phospho-Elk1 antibody followed by incuba-
tion with horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG (Amersham Biosciences, Piscataway, NJ,
USA). The Phototope-HRP Western Blot Detection
System method (Cell Signaling) was used for color de-
velopment.
Formation of cross-linked fibrin on human mesangial
cell surface
Human mesangial cells (1.2 × 104 cells per chamber)
were cultured on Lab-Tec chamber slides (Nalge Nunc
International) coated with fibronectin (Sigma Chemi-
cal Co.), and subconfluent mesangial cells were serum
starved for 48 hours to wash out cell surface-binding
coagulation factors. Mesangial cells were incubated for
another 24 hours with 100 U/mL of TNF-a at 37◦C in
serum-free media, to express endogenous factor V as pre-
viously reported [4]. Human mesangial cells were then
incubated for another 60 minutes with 1.7 lmol/L factor
Xa, 27.7 lmol/L prothrombin, 3.2 lmol/L factor XIII,
and 7.6 lmol/L fibrinogen in the presence or absence
of 10 lmol/L DX-9065a. Cells were then fixed in 2%
paraformaldehyde in PBS for 15 minutes at 37◦C, washed
with ice-cold PBS three times, and stored at−20◦C. Cross-
linked fibrin deposition was detected indirectly after
plasmin exposure using a monoclonal antibody against
D-dimer (American Diagnostica, Inc.). Mesangial cells
on the chamber slides were incubated with normal horse
serum (Vector Laboratories, Burlingame, CA, USA) for
10 minutes to block the nonspecific binding. Mesangial
cells were incubated with the primary antibody against
D-dimer for 1 hour followed by biotinylated horse anti-
mouse IgG (Vector Laboratories). Mesangial cells were
then reacted with avidin-DH-biotinylated HRP complex
(Vector Laboratories) for 15 minutes. Color was then de-
veloped by incubation with an ImmunoPure Metal En-
hanced DAB Substrate kit (Pierce). Mesangial cells were
counterstained with hematoxylin.
Immunostaining of mesangial cells for PAR2
Cultured human mesangial cells were transferred Lab-
Tec chamber slides and grown to subconfluent. Then they
were serum starved for 48 hours and the medium was
replaced with fresh starving medium for 24 hours con-
taining 50 nmol/L factor Xa with or without 10 lmol/L
DX-9065a, or left untreated. Mesangial cells were fixed
with 2% paraformaldehyde and immunostained with a
mouse monoclonal antihuman PAR2 antibody for 1 hour
followed by biotinylated horse antimouse IgG antibody
(Vector Laboratories). Mesangial cells were then reacted
with avidin-DH-biotinylated HRP complex (Vector Lab-
oratories) before color development. The staining inten-
sity of PAR2 was then analyzed.
Reverse transcription-polymerase chain reaction
(RT-PCR) for PAR mRNA
After human mesangial cells were grown to subcon-
fluence in the media containing 20% FCS for 48 hours,
total RNA was isolated by the use of Trizol Reagent
(Invitrogen). First-strand cDNA synthesis was made from
1 lg of total RNA using ThermoScriptTM RT-PCR Sys-
tem for First-Strand cDNA Synthesis following recom-
mended protocols (Invitrogen). The reaction was per-
formed at 50◦C for 1 hour. Subsequently, the reverse
transcriptase was inactivated by heating the sample at
85◦C for 5 minutes. cDNA was then amplified by using
primers based on human PAR1, PAR2, PAR3, PAR4, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
using Thermal cycler (Peltier Thermal Cycler) (MJ Re-
search, Waltham, MA, USA). PAR1 primers 5′-CTC
GTC CTC AAG GAG CAA AC-3′ and 5′-TAA CTG
CTG GGA TCG GAA CT-3′; PAR2 primers 5′-CCC
TTT GTA TGT CGT GAA GC-3′ and 5′-TTC CTG
GAG TGT TTC TTT GAG G-3′; PAR3 primers 5′-ACT
GTG AGC CTT CTG GTC TT-3′ and 5′-GAT TCA TCA
AGC CCC TCA ATC C-3′; PAR4 primers 5′-CTG GGC
AAC AGA GCA AGA-3′ and 5′-CCA GAA GTC CAG
GGT CAA G-3′; and GAPDH primers 5′-TCA CCA
GGG CTG CTT TTA ACT C-3′ and 5′-GGA CTG TGG
TCA TGA GTC CTT C-3′, respectively, were designed
from published human PAR1, 2, 3, 4, and GAPDH se-
quences [31]. The PCR reaction consisted of a 5-minute
denaturation step at 94◦C, followed by 30 cycles of 30 sec-
onds at 94◦C, 15 seconds at 50◦C, and 1 minute at 72◦C.
The reaction was terminated after 5 minutes at 72◦C.
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Fig. 1. Effect of DX-9065a on mitogenic effects of factor Xa (FXa), thrombin, and SLIGKV in mesangial cells. (A) Dose-dependent increase in
DNA synthesis by factor Xa in mesangial cells. After serum starvation for 48 hours, the medium was replaced with fresh starving medium containing
factor Xa at the indicated concentrations. After 18 hours, [3H]-thymidine was added to the medium, and 6 hours later [3H]-thymidine incorporation
was determined as described in the Methods section. Results are expressed as means ± SD (N = 4). (B) Inhibition of factor Xa–stimulated
[3H]-thymidine incorporation by DX-9065a. After pretreatment with or without DX-9065a (1 or 10 lmol/L) for 1 hour and mesangial cells were
stimulated with factor Xa (50 nmol/L) for 18 hours. [3H]-thymidine incorporation was then determined. Results are expressed as means ± SD (N
= 4). (C) Lack of effect of DX-9065a on thrombin- or SLIGKV-induced DNA synthesis in mesangial cells. After pretreatment with DX-9065a (10
lmol/L) or recombinant hirudin (10 U/mL) for 1 hour, mesangial cells were stimulated with thrombin (10 nmol/L) or SLIGKV (50 lmol/L) for 18
hours. [3H]-thymidine incorporation was then determined. Results are expressed as means ± SD (N = 4). ∗P < 0.05; ∗∗P < 0.01.
Amplifications of each appropriate cDNA result in 482
bp, 525 bp, 530 bp, 585 bp, and 483 bp fragment for PAR1,
PAR2, PAR3, PAR4, and GAPDH. The PCR products
were separated in 2% agarose gels.
Statistical analysis
Results are shown as mean values ± SD. One-way anal-
ysis of variance (ANOVA) followed by Bonferroni/Dunn
test was used to evaluate the statistical significance be-
tween each group. A P value of <0.05 was considered to
be significant.
RESULTS
Effect of factor Xa and DX-9065a on proliferation of
mesangial cells
To examine whether factor Xa can act as a mitogen
for human mesangial cells, we measured [3H]-thymidine
incorporation after incubation with various concentra-
tions of factor Xa. As shown in Figure 1A, factor Xa
induced a dose-dependent increase in DNA synthesis at
concentrations up to 100 nmol/L, with a 2.7-fold increase
at maximum. Pretreatment of the cells with 1 or 10 lmol/L
DX-9065a inhibited this increase by 72.6% or 62.5%,
respectively (Fig. 1B). However, a specific thrombin in-
hibitor, recombinant hirudin did not affect the mitogenic
effect of factor Xa in human mesangial cells. Thrombin,
on the other hand, increased [3H]-thymidine incorpora-
tion at 10 nmol/L by 1.52-fold. This increase was inhibited
by 64.4% with 10 U/mL recombinant hirudin (data not
shown), but was not affected by 10 lmol/L DX-9065a.
We also examined the effect of PAR2-activating pep-
tides, SLIGKV on DNA synthesis and found that 50
lmol/L SLIGKV increased [3H]-thymidine incorpora-
tion by 1.4-fold. DX-9065a also did not affect SLIGKV-
induced DNA synthesis (Fig. 1C).
The effect of factor Xa on human mesangial cells
proliferation was also confirmed by WST-1 assay. The
number of human mesangial cells was increased dose-
dependently by stimulation with factor Xa at concentra-
tions up to 100 nmol/L (Fig. 2A), and pretreatment of
the cells with 1 or 10 lmol/L DX-9065a inhibited this in-
crease dose-dependently by 90.9% or 88.6%, respectively
(Fig. 2B). The stimulation by thrombin and SLIGKV also
induced an increase of cell proliferation. The increase in
cell number induced by SLIGKV or thrombin was not
affected by the pretreatment with 10 lmol/L DX-9065a
(Fig. 2C).
Evaluation of cell viability
We measured the LDH release after incubation with 1
or 10 lmol/L DX-9065a to examine the cytotoxic effect of
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Fig. 2. Effect of DX-9065a on cell number increase induced by factor Xa (FXa), thrombin, and SLIGKV in mesangial cells. (A) Mesangial cells
were plated on 96-well plates. After serum starvation for 48 hours, the medium was replaced with fresh serum-free medium containing factor Xa at
the indicated concentrations. After 20 hours, 10 lL of premix WST-1 solution was added to the medium, and the optical density was then determined
4 hours later as described in the Methods section. The control was expressed as 100%. Results are expressed as means ± SD (N = 8). (B) Effect
of DX-9065a on factor Xa–induced proliferation in mesangial cells. The cells were pretreated with DX-9065a (1 or 10 lmol/L) for 1 hour before
stimulation with factor Xa (50 nmol/L) for 20 hours. The cell number was then determined. Results are expressed as means ± SD (N = 8). (C)
Effect of DX-9065a on thrombin and SLIGKV-induced cell number increase in mesangial cells. After pretreatment with DX-9065a (10 lmol/L) or
recombinant hirudin (10 U/mL) for 1 hour, mesangial cells were stimulated with the indicated concentrations of thrombin (10 nmol/L) or SLIGKV
(50 lmol/L) for 20 hours. The cell number was then determined. Results are expressed as means ± SD (N = 8). ∗P < 0.05; ∗∗P < 0.01.
Table 1. Lactate dehydrogenase (LDH) release after incubation with
factor Xa inhibitor DX-9065a
LDH release (%)
Control 10.9 ± 5.0
DX-9065a
1 lmol/L 10.4 ± 2.4
10 lmol/L 12.7 ± 4.5
LDH was measured in culture supernatants and in cell lysates. The percentage
of LDH release was calculated from the ratio of supernatants/(supernatants +
cell lysates). Data are expressed as the mean ± SD.
DX-9065a. LDH was measured in culture supernatants
and in the cell lysate. The percentage of LDH release was
calculated from the ratio of supernatant/(supernatant +
cell lysate). Table 1 shows the LDH release of control was
10.9 ± 5.0%, while LDH release after treatment with 1
or 10 lmol/L DX-9065a was 10.4 ± 2.4 or 12.7 ± 4.5%,
respectively. There was no significant difference of LDH
release after stimulation with DX-9065a compared with
the control.
Effect of factor Xa and DX-9065a on activation of ERK
We next examined whether factor Xa can affect
the signaling pathway involved in cell proliferation in
human mesangial cells. We therefore measured the
cellular ERK activity after stimulation with factor Xa
in human mesangial cells. Factor Xa–induced ERK ac-
tivation was peaked at 15 minutes and declined there-
after (Fig. 3A). EC50 of factor Xa for ERK activation
was approximately 5 nmol/L (Fig. 3B). We also exam-
ined the time course of ERK activation after stimulation
with SLIGKV, and found that the peak was at 5 min-
utes (Fig. 3C). In a dose-response experiment, SLIGKV
induced ERK activation in a dose-dependent fashion
(Fig. 3D). Thrombin also caused activation of ERK
at 5 minutes (data not shown). Treatment with DX-
9065a before stimulation with 50 nmol/L factor Xa inhib-
ited the factor Xa–dependent ERK activation. However,
thrombin-induced ERK activation was not affected by
DX-9065a (Fig. 4).
Inhibition of factor Xa–induced cell proliferation
and ERK activation by PD98059
To examine whether activation of ERK is required for
cell proliferation induced by factor Xa and thrombin,
we treated the cells with 25 or 50 lmol/L PD98059 be-
fore stimulation with 50 nmol/L factor Xa. As shown in
Figure 5, pretreatment of the cells with PD98059 inhib-
ited factor Xa–induced cell proliferation and ERK acti-
vation, indicating that the effect of factor Xa and on cell
proliferation is dependent on ERK.
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Fig. 3. Activation of extracellular regulated kinase (ERK) by factor
Xa (FXa), SLIGKV or thrombin in mesangial cells. (A) After serum
starvation for 48 hours, cells were incubated with factor Xa (50 nmol/L)
for the indicated periods of time. Phosphorylation of Elk-1 was then de-
termined to assess ERK activation by Western blotting as described in
the Methods section. (B) After serum starvation, cells were stimulated
with the indicated concentrations of factor Xa for 15 minutes. Phospho-
rylation of Elk-1 was then determined. (C) After serum starvation, cells
were stimulated with SLIGKV (50 lmol/L) for the indicated times or
stimulated with the indicated concentrations SLIGKV for 5 minutes.
(D) Phosphorylation of Elk-1 was then determined. Each figure shows
a representative result from four independent experiments.
Effect of FR171113 on PAR1- and PAR2-dependent
ERK activation
To examine whether factor Xa can activate ERK specif-
ically via PAR2 in mesangial cells, the cells pretreated
with or without 1 lmol/L FR171113 were stimulated with
PAR1 or PAR2 agonists. As shown in Figure 6, pretreat-
ment of the cells with FR171113 inhibited thrombin- and
SFLLRN-induced ERK activation, but not factor Xa- or
SLIGKV-induced ERK activation, indicating that acti-
vation of ERK by factor Xa is specifically mediated by
PAR2.
Formation of cell surface cross-linked fibrin by factor Xa
Cross-linked fibrin production on mesangial cells was
examined immunohistochemically by anti-D-dimer anti-
body after plasmin exposure. Cross-linked fibrin forma-
tion was augmented on mesangial cell surface after the
addition of factor Xa, prothrombin, XIII, and fibrinogen
(Fig. 7). The addition DX-9065a caused a significant inhi-
bition of cross-linked fibrin production on the mesangial
cell surface.
Immunostaining of mesangial cells for PAR2
To examine the involvement of PAR2, PAR2 expres-
sion in human mesangial cells was examined by immuno-
histochemistry (Fig. 8). Immunoreactive PAR2 was de-
tected in cultured human mesangial cells. Further, PAR2
expression was predominantly cytoplasmic and perinu-
clear. We also found that factor Xa induced expression
of PAR2, which was inhibited by the treatment of the cells
with 10 lmol/L DX-9065a.
RT-PCR for PAR1, 2, 3, and 4 mRNA
We examined the expression of PAR1, 2, 3, and 4
mRNA in human mesangial cells by RT-PCR. As shown
in Figure 9, human mesangial cells expressed PAR1, 2,
and 3, but not PAR4. Agarose gel analysis of the PCR re-
actions showed amplification of predicted 557, 525, and
530 bp fragments of PAR1, 2, and 3 mRNA in human
mesangial cells, respectively.
DISCUSSION
In this study, we showed that factor Xa could induce
proliferation of cultured mesangial cells and activation
of ERK in a PAR-dependent manner in vitro. We also
showed that DX-9065a, a specific inhibitor of factor Xa,
inhibited these effects and cross-linked fibrin depositions
on human mesangial cells, suggesting a role of factor Xa
and PARs in mesangial cell proliferation and coagulation
in mesangium.
Human mesangioproliferative glomerulonephritis is
histologically characterized by mesangial cell prolifera-
tion and mesangial matrix expansion in the glomeruli
[32] along with the acceleration of intraglomerular co-
agulation cascades [1, 33]. Several studies also show the
role of tissue factor and tissue factor pathway inhibitor
in human crescentic glomerulonephritis [34, 35]. Re-
cently, we reported the role of mesangial factor V expres-
sion in crescentic formation through mesangiolysis and
glomerular basement membrane break [36] and in the
extracellular matrix accumulation through up-regulated
production of matrix components in rat mesangioprolif-
erative glomerulonephritis [33]. Thus the role of coagu-
lation cascades in glomerulonephritis should be stressed
to understand its pathogenesis. In vivo, the mesangial
coagulatory events seem to happen in three conditions:
physiologic, activated, and exaggerated states. However,
in vitro, mesangial cells are already activated, but not
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Fig. 4. Inhibition of factor Xa(FXa)-induced
extracellular regulated kinase (ERK) activa-
tion by DX-9065a. (A) Mesangial cells were
serum starved for 48 hours. After pretreat-
ment with the indicated concentrations of
DX-9065a for 60 minutes, cells were incu-
bated with factor Xa (50 nmol/L) for 15
minutes. Phosphorylation of Elk-1 was then
determined. (B) Cells were incubated with or
without DX-9065a (10 lmol/L) for 60 minutes
before stimulation with factor Xa (50 nmol/L)
for 15 minutes or thrombin (10 nmol/L) for 5
minutes. Phosphorylation of Elk-1 was then
determined. Each figure shows a represen-
tative result from four independent experi-
ments.
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Fig. 5. Inhibition of factor Xa (FXa)-induced
cell proliferation and extracellular regulated
kinase (ERK) activation by PD98059. (A)
Mesangial cells were plated on 96-well plates
and serum starved for 48 hours. After pre-
treatment with the indicated concentrations
of PD98059 (25 or 50 lmol/L) for 60 min-
utes, cells were incubated with factor Xa (50
nmol/L) for 20 hours. The optical density
was determined by WST-1 as in Figure 2A.
∗P < 0.05; ∗∗P < 0.01. (B) Cells were in-
cubated with or without PD98059 (25 or 50
lmol/L) for 60 minutes before stimulation
with factor Xa (50 nmol/L) for 15 minutes.
Phosphorylation of Elk-1 was then deter-
mined as described as Figure 3A. Each figure
shows a representative result from four inde-
pendent experiments.
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Fig. 6. Effect of FR171113 on extracellu-
lar regulated kinase (ERK) activation by
protease-activated receptor 1 (PAR1) and
PAR2 agonists. Mesangial cells were serum
starved for 48 hours. After pretreatment
with or without FR17113 (1 lmol/L) for 30
minutes, cells were incubated with throm-
bin (10 nmol/L) for 5 minutes (A), SFLLRN
(100 lmol/L) for 5 minutes (B), factor Xa (50
nmol/L) for 15 minutes (C), or SLIGKV (50
lmol/L) for 5 minutes (D). Phosphorylation
of Elk-1 was then determined. Each figure
shows a representative result from four inde-
pendent experiments.
involved in necrosis yet. As our in vitro data indicate,
the experimental results might correlate with the acti-
vated state in vivo, causing intramesangial coagulation to-
gether with mesangial proliferation. Therefore, factor Xa
might also be an important target to regulate the disease
process.
Accumulating evidence indicates that ERK plays an
important role in the cell proliferation [37] and that ERK
is a putative intracellular mediator of proliferative re-
sponse in glomerulonephritis in vivo [38]. In addition to
the effect of factor Xa as blood coagulants, factor Xa is
known to act as a potent mitogen for mesanigal cells [5],
endothelial cells [39], fibroblasts [40], and aortic smooth
muscle cells [41–45]. We showed in this study that factor
Xa induced mesangial cell proliferation and plays the im-
portant role in the coagulation cascades by the result of
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Fig. 7. Inhibition of cross-linked fibrin (XFb) formation by DX-9065a. Mesangial cells were cultured on Lab-Tec chamber slides coated with
fibronectin. After serum starvation for 48 hours, cells were then incubated with tumor necrosis factor-a (TNF-a) (100 U/mL) in serum-free media
for 24 hours, followed by the incubation with factor Xa (1.7 lmol/L), prothrombin (27.7 lmol/L), factor XIII (3.2 lmol/L), and fibrinogen (7.6
lmol/L) in the presence or absence of DX-9065a (10 lmol/L) for 1 hour. Cross-linked fibrin deposition was detected indirectly after plasmin
exposure using a monoclonal antibody against D-dimer. (A) Cells showed untreated mesangial cells. (B) Cells treated with factor Xa. (C) Cells
treated with factor Xa and DX-9065a (1 lmol/L). (D) Cells treated with factor Xa and DX-9065a (10 lmol/L) (final magnification ×400).
fibrin deposition on the mesangial surface, and that factor
Xa could cause a mitogenic effect in an ERK-dependent
manner in human mesangial cells. It is assumed that fac-
tor Xa binds to the fibrin clot and thereby contributes
to further activation of the coagulation system [46–48].
After factor Xa stimulates fibrin deposition through the
formation of thrombinase, clot-binding factor Xa contin-
ues to activate prothrombin to thrombin. These series
of action of coagulation cascade can also stimulate the
mesangial cell proliferation. However, inhibition of fac-
tor Xa would be very effective to regulate the mesangial
cell proliferation, because factor Xa plays a major role in
the coagulation cascades.
We showed mesangial cell activation by PAR2-agonist
peptides. Other studies also show that SLIGKV increases
[3H]-thymidine incorporation in human airway smooth
muscle cells [49], coronary artery smooth muscle cell
[44], and extravillous trophoblasts [50]. In our present im-
munohistochemical study, PAR2 was expressed in mesan-
gial cells, and its expression was increased after stimula-
tion with factor Xa. This induction of PAR2 expression
was inhibited by DX-9065a. In this study, we showed that
thrombin- and SFLLRN-induced ERK activation was in-
hibited by FR171113, but not factor Xa- or SLIGKV-
induced ERK activation. Thus our results indicate that
PAR2 plays a pivotal role in factor Xa–mediated signal-
ing in human mesangial cells.
PARs are G protein–coupled receptors, which acti-
vate numerous cellular signaling pathways. In this study,
PAR1, 2, and 3 mRNA, but not PAR4 were detected
in mesangial cells. In PAR1-deficient mice, reduced
glomerular fibrin deposition and glomerular mononu-
clear inflammatory cell infiltration was found in a cres-
centic glomeruronephritis model [51]. PAR2 is a unique
receptor among PARs in terms of its broad ligand speci-
ficity and plays roles in inflammation of the lung, gastroin-
testinal system, nervous system, skin, joint, and kidney
[52]. Although the progression of glomerulonephritis in
Fig. 8. Expression of protease-activated receptor 2 (PAR2) in human
mesangial cells by immunocytochemistry. (A) Cells without primary an-
tibody. Serum-starved cells were incubated with factor Xa (50 nmol/L)
for 24 hours after pretreatment with or without DX-9065a (10 lmol/L)
for 1 hour. Cells were then fixed and immunostained with anti-PAR2
antibody. (B) Control cells showed untreated mesangial cells. (C) Cells
were treated with factor Xa. (D) Cells stimulated with factor Xa after
pretreatment with DX-9065a (final magnification ×200).
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Fig. 9. Expression of protease-activated receptors (PARs) by re-
verse transcription-polymerase chain reaction (RT-PCR). After human
mesangial cells were grown to subconfluence in the media contain-
ing 20% fetal calf serum (FCS) for 48 hours, total RNA was isolated.
RT-PCR was done as described in the Methods section. GAPDH is
glyceraldehyde-3-phosphate dehydrogenase.
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PAR2-deficient mice is not known, the development of
glomerulonephritis can be regulated by PAR2 and acti-
vation of coagulation factors in vivo.
The role of PAR3 in mesangial cells is not yet clarified.
Studies with PAR3-deficient mice [53] and PAR3-agonist
peptides [13] demonstrated that mouse PAR3 plays an
important role in the platelet activation by thrombin, but
dose not signal without the presence of PAR4. Because
we could not show the expression of PAR4 in mesangial
cells, PAR3 might not play a role in mesangial prolifera-
tion.
CONCLUSION
Our data suggest that factor Xa can induce mesan-
gial cell proliferation through the activation of ERK via
PAR2 in mesangial cells and that PAR2 may play a crucial
role in the cell proliferation induced by factor Xa. Reg-
ulating the factor Xa activity with its specific inhibitor,
DX-9065a, could be a potential therapeutic approach
for the active type of human mesangioproliferative
glomerulonephritis.
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